Study: NCT03903835

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enzalutamide Oral Capsule
Description: Detailed conditions for the use of the study treatments including dose and dosages are described in accordance with the marketing authorization in the SmPC (Summary of Product Characteristics).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide Oral Capsule
Description: Detailed conditions for the use of the study treatments including dose and dosages are described in accordance with the marketing authorization in the SmPC (Summary of Product Characteristics).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide Oral Capsule
Description: Detailed conditions for the use of the study treatments including dose and dosages are described in accordance with the marketing authorization in the SmPC (Summary of Product Characteristics).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Abiraterone Oral Tablet
Description: Detailed conditions for the use of the study treatment including dose and dosages are described in accordance with the marketing authorisation in the SmPC.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone Oral Tablet
Description: Detailed conditions for the use of the study treatment including dose and dosages are described in accordance with the marketing authorisation in the SmPC.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone Oral Tablet
Description: Detailed conditions for the use of the study treatment including dose and dosages are described in accordance with the marketing authorisation in the SmPC.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone Oral Tablet
Description: Detailed conditions for the use of the study treatment including dose and dosages are described in accordance with the marketing authorisation in the SmPC.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin will be administered every 3rd week with an AUC (area under curve) = 5 with a dose calculated according to the Carboplatin AUC Dose calculation (Calvert formula):Dose (mg) = TargetAUC (mg/ml x min) x \[GFR ml/min + 25\].

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cabazitaxel 60 mg Solution for Injection
Description: Detailed conditions for the use of the study treatment including dose and dosages are described in accordance with the marketing authorisation in the SmPC.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel Injectable Solution
Description: Detailed conditions for the use of the study treatment including dose and dosages are described in accordance with the marketing authorisation in the SmPC.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel Injectable Solution
Description: Detailed conditions for the use of the study treatment including dose and dosages are described in accordance with the marketing authorisation in the SmPC.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Radium Chloride Ra-223
Description: Detailed conditions for the use of the study treatment including dose and dosages are described in accordance with the marketing authorisation in the SmPC.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niraparib plus Abiraterone acetate plus Prednisone
Description: Niraparib and Abiraterone acetate will be provided by Janssen and will be provided either as a fixed dose combination or as single agents. Detailed use of the study treatment including dose and dosages are described in the Investigator's brochures and SmPC.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niraparib plus Abiraterone acetate plus Prednisone
Description: Niraparib and Abiraterone acetate will be provided by Janssen and will be provided either as a fixed dose combination or as single agents. Detailed use of the study treatment including dose and dosages are described in the Investigator's brochures and SmPC.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capivasertib plus Docetaxel
Description: Capivasertib is provided by AstraZeneca and will be given in combination with Docetaxel. All subjects will be given up to ten 21-day docetaxel cycles. All subjects will receive Capivasertib, which will be administered as tablets taken twice a day orally, on a 4 days on/3 days off continuous schedule, commencing cycle one, day 2, until disease progression.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Apalutamide
Description: Detailed conditions for the use of the study treatments including dose and dosages are described in accordance with the marketing authorization in the SmPC (Summary of Product Characteristics).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apalutamide
Description: Detailed conditions for the use of the study treatments including dose and dosages are described in accordance with the marketing authorization in the SmPC (Summary of Product Characteristics).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darolutamide
Description: Detailed conditions for the use of the study treatments including dose and dosages are described in accordance with the marketing authorization in the SmPC (Summary of Product Characteristics).